Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer
European Journal of Cancer · 2026-10 · 247 · 117040
DOI: 10.1016/j.ejca.2026.117040 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-10. Verfasst von Sai Agash Surendran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Hand Surgery, Freiburg University Hospital, Freiburg, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, DNA, Bacterial. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Monitoring therapy response in pancreatic cancer (PDAC) remains challenging. The microbiome affects therapy efficacy, but its role in response prediction is unclear. We assessed whether changes in circulating free bacterial DNA (cfbDNA) levels predict outcome of advanced PDAC (aPDAC) patients treated with systemic chemotherapy. PATIENTS AND METHODS: We analyzed the prognostic impact of serum cfbDNA dynamics of 13 patients with aPDAC receiving mFOLFIRINOX (FFX) before treatment initiation and after two chemotherapy cycles. We validated the findings in the samples of 47 patients with locally advanced pancreatic cancer from the NEOLAP-AIO-PAK-0113 trial. RESULTS: Decreased cfbDNA during FFX treatment was associated with improved PFS (14.3 vs. 2.9 months; p < 0.001) and OS (23.2 vs. 8.4 months; p = 0.006) in the exploratory cohort. Equal or increased cfbDNA was associated with inferior OS in univariate analyses (HR, 7.74; 95% CI, 1.38-43.24; p = 0.020) and a model adjusted for CA-19-9 group (HR, 11.75; 95% CI, 1.87-73.85; p = 0.009). In the NEOLAP cohort, decreased cfbDNA was associated with improved PFS (12.4 vs. 8.7 months, p = 0.003) and OS (39.8 vs. 14.7 months, p = 0.001) in FFX treated patients, whereas in patients continuing on gemcitabine plus nab-paclitaxel (GnP), decreased cfbDNA was associated with shorter PFS (6.2 vs. 11.5 months, p < 0.001) and OS (12.9 vs. 18.8 months, p = 0.013). CONCLUSIONS: cfbDNA dynamics may serve as blood-based biomarker for monitoring therapy response in aPDAC. Its treatment-dependent predictive impact may inform clinical decisions. These findings suggest therapy-specific host-microbiome-tumor interactions and warrant prospective validation. CLINICAL TRIAL NUMBER: NCT02125136.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Hand Surgery, Freiburg University Hospital, Freiburg, Germany.
- Institute of General Pathology, Medical University Innsbruck, Innsbruck, Austria.
- Department of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
- Department of Medicine III and Comprehensive Cancer Center, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Department…
- Department of Internal Medicine II, Medical Oncology, University Hospital Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
- Institute of General Pathology, Medical University Innsbruck, Innsbruck, Austria. Electronic address: steffen.ormanns@i-med.ac.at.
Zitieren
APA
Surendran, S. A., Guenther, M., Nemati, N., Incera, M. L., Zhang, D., Boeck, S., Heinemann, V., Kimmel, B., Kunzmann, V., & Ormanns, S. (2026). Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. European Journal of Cancer, 247, 117040. https://doi.org/10.1016/j.ejca.2026.117040
Vancouver
Surendran SA, Guenther M, Nemati N, Incera ML, Zhang D, Boeck S, et al. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. European Journal of Cancer. 2026;247:117040. doi:10.1016/j.ejca.2026.117040
BibTeX
@article{Surendran2026,
author = {Surendran, Sai Agash and Guenther, Michael and Nemati, Niloofar and Incera, Marina Lopez and Zhang, Danmei and Boeck, Stefan and Heinemann, Volker and Kimmel, Brigitte and Kunzmann, Volker and Ormanns, Steffen},
title = {Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {247},
pages = {117040},
doi = {10.1016/j.ejca.2026.117040}
}
EUVIMED